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Abstract 
Herpes Zoster (HZ) is an acute, painful rash characterized by vesicular lesions following a 
dermatome.  The incidence of HZ in North America ranges from 3-5/1000 person-years with 
increasing incidence accompanying age and over time, even after implementation of the varicella 
vaccination program (Kawai, Gebremeskel, & Acosta, 2014).  Post-herpetic neuralgia (PHN) is 
the most common complication of HZ with an incidence from 7.9-31.9% in the United States 
(Kawai et al., 2014).  A 52-year-old male was seen in the clinic with an acute episode of HZ.  He 
reported moderate, neuropathic-type pain and expressed concern over the possibility of 
developing PHN and the availability of effective pain management.   There is an unmet need in 
the management of PHN as current treatments provide only modest results and are dose-limited 
due to side effects (Finnerup et al., 2015).  A literature review was conducted in order to identify 
emerging therapies in the prevention and management of PHN and whether their benefit exceeds 
that of current first-line treatment options.  Several novel agents were found that have shown 
equal, if not greater, efficacy in early studies.  These include: EMA401, a highly selective 
angiotensin II type 2 receptor antagonist, HZ/su, a novel conjugate VZ subunit vaccine, and 
various modes of neuromodulation.   
 Keywords: Post-herpetic neuralgia, EMA401, HZ/su vaccine, neuromodulation 
  
4 
MANAGEMENT OF POST-HERPETIC NEURALGIA 
Novel Agents and Comparative Efficacy in the Prevention and Management of Post-
Herpetic Neuralgia 
The incidence of HZ in North America ranges from 3-5/1000 person-years with the 
incidence sharply increasing after 50 years of age, with a rate of about 2/1000 person-years at 
age 40, 6-8/1000 person-years at age 60, and up to 8-12/1000 person-years at age 80 (Kawai, 
Gebremeskel, & Acosta, 2014).  For unknown reasons, the incidence continues to rise even in 
the post-vaccination program era (Kawai et al., 2014).  Post-herpetic neuralgia (PHN) is the most 
common complication of HZ with an incidence of 7.9-31.9% in the United States (Kawai et al., 
2014) and it is the third most common type of neuropathic pain, trailing behind neuropathic low-
back pain and diabetic neuropathy (Bennett, 1995).  Kawai et al.’s analysis and review of 
literature included studies conducted in various geographic regions of the United States and with 
varying patient populations, which accounts for the wide range of incidence dependent on study 
design.  PHN is the most common complication of HZ infection, and it is not only associated 
with chronic pain, but with effects on physical and mental health, daily activities, and quality of 
life (Johnson et al., 2010).  With the growing population of persons over the age of 60 and the 
increasing incidence of HZ (Kawai et al., 2014), there is a significant need for effective pain 
management as current treatment options provide only modest results (Finnerup et al., 2015).   
A systematic review by Finnerup et al. of 229 articles and/or trials was published in 2015 
evaluating the currently available and commonly used pharmacologic treatments for all types of 
neuropathic pain caused by a disease of the somatosensory nervous system.  PHN was one of the 
identified causative conditions included in the review.  Finnerup et al. found little evidence 
supporting greater efficacy of a certain class of drug for each specific neuropathic pain disorder.  
Strong recommendations for first-line treatment were made for tricyclic antidepressants, 
5 
MANAGEMENT OF POST-HERPETIC NEURALGIA 
serotonin-noradrenaline reuptake inhibitors, gabapentin, and pregabalin based on the grades of 
recommendation, assessment, development, and evaluation (GRADE) system (Finnerup et al., 
2015).  However, only modest outcomes were achieved for these drug classes, with the number 
needed to treat (NNT) for a 50% reduction of pain ranging from 3.6 with tricyclic 
antidepressants to 7.7 with pregabalin (Finnerup et al., 2015).  Finnerup et al. concluded that 
there is a significant, unmet need for satisfactory pain control in patients with neuropathic pain, 
including those with PHN.   
Although there are inconsistent results on the efficacy of the current varicella vaccination 
program in decreasing the incidence of HZ, it is the only proposed method of preventing HZ and 
PHN (Kawai et al., 2014).  A Cochrane Review found no evidence that the use of early antiviral 
therapy significantly reduces the risk of developing PHN (Chen, Li, Yang, Zhou, & He, 2014).  
With the increasing incidence of VZ and the lack of effective treatments for PHN, there is a need 
for research to identify novel agents for the prevention and management of PHN. 
Case Report 
Subjective 
M.D. was a 52-year-old Caucasian male who presented to the walk-in clinic on 2/5/2016.  
His chief complaint was a rash to his face.  Approximately a week prior to the visit, the patient 
had developed a “burning sensation” to the area lateral of his left eye extending to the temple 
area which went away after a few days.  A few days after the resolution of the burning sensation, 
the patient noticed erythema to the same area along with several intact blistered areas.  The 
patient reported burning, tingling pain to this area rated 6/10 on 0-10/10 pain scale, which waxed 
and waned throughout the day with no identified worsening factors.  Acetaminophen improved 
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his pain slightly.  The patient also reported some blurred vision to his left eye, qualifying his left 
eye acuity as being “a degree off of normal”.    He denied eye pain or discharge, denied any 
scleral injection, and denied any rash extending to eyelid or forehead.  Patient reports an increase 
in work-related stress as of late.  All other systems were reviewed and negative.  The patient had 
a history of chicken pox as a child and reports use of corrective lenses for myopia.  All other 
family and personal histories were reviewed and noncontributory.   
Objective 
On examination, M.D. was a well-developed, 52 year-old Caucasian male who appeared 
stated age.  Patient appeared comfortable, and was jovial, alert and cooperative throughout the 
exam.  His vital signs were as follows: blood pressure 152/92, heart rate 88, respiratory rate 16, 
temperature 97.4, weight 140 pounds, and pain 6/10.  Height and BMI were not obtained.  Head 
was normocephalic, atraumatic, and with symmetric facial features.  Eyelids and forehead were 
without rash or edema.  No ptosis was observed.  Sclera were anicteric, conjunctiva were clear 
and noninjected, no opacities to cornea, and pupils were equal, round, and reactive to light both 
direct and consensual.  Ears and nose were without rash or lesions.  A crescent moon-shaped area 
lateral of left eye along V2 dermatome was reddened with three serous-fluid-filled vesicles 
noted.  No crusted areas at that time.  The rash was isolated to this area with skin being otherwise 
unremarkable.  Other aspects of the examination were without abnormal findings. 
Assessment and Plan 
Based on clinical findings, a diagnosis of HZ was made.  Antiviral medication options 
were discussed with the patient and acyclovir 800 mg orally, five times daily for seven days was 
chosen by the patient as it was the least expensive treatment regimen.  For pain management, 
7 
MANAGEMENT OF POST-HERPETIC NEURALGIA 
acetaminophen and tramadol were prescribed.  Patient was to follow up on Monday or present to 
the emergency room if any worsening of vision or extension of lesions into eye, eyelid, or 
forehead occurred.  Patient verbalized agreement with the plan, but expressed concern and 
anxiety at the possibility of long-term pain related to shingles.  There were also incidental 
findings of elevated blood pressure at the visit as well as health maintenance items which were 
not up to date.  A physical examination appointment was scheduled for him with his primary 
care provider in order to address these items as well as any other non-acute health concerns. 
Literature Review 
Relevant research of the novel pharmacologic and nonpharmacologic treatment 
modalities for PHN was identified by searching PubMed, CINAHL, Google Scholar, and the 
Cochrane Library.  Search terms used in various combinations include: treatment, management, 
post-herpetic, neuralgia, neuropathic pain, shingles, and herpes zoster.  Results for potential 
therapies or treatments were limited to those articles published from 2011-2016.  Articles were 
further narrowed down by those demonstrating therapeutic value as future therapies, those 
available in English and to studies performed on human participants.  Several articles were 
obtained via the reference lists of literature acquired via the search. 
The 52-year-old male patient’s primary concern at the time of examination was that of 
the possibility of developing PHN.  Nearly a third of persons with HZ infection may develop 
PHN (Thyregod, 2007).  Johnson et al. (2010) found in multiple long-term, prospective cohort 
studies that more than 30% of persons with PHN may have neuropathic pain persisting for a 
duration of greater than one year.   Chronic pain impacts quality of life, creates physical 
disability as well as emotional distress, and causes a loss of productivity (Johnson et al., 2010).  
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The current treatment options for PHN have shown only modest efficacy and there exists an 
unmet need for pain control in this population (Finnerup et al., 2015). 
EMA401 
Neuropathic pain is defined as “pain caused by a lesion or disease of the somatosensory 
nervous system” (Jensen et al., 2011, p. 2204).  EMA401, which is a highly selective angiotensin 
II type 2 receptor (AT2R) antagonist, is an oral medication being evaluated for therapeutic 
potential in the management of neuropathic pain (Rice et al., 2014).  While one of the roles of 
the angiotensin II type 1 receptors is to modulate blood pressure, the AT2R receptor does not 
have this effect, but instead may play a role in the nervous system and nociception (Anand et al., 
2013).  Anand et al. (2013) found that when capsaicin, a compound found in chili peppers, acts 
on receptors in pain sensory neurons it causes an influx of calcium which creates the sensation of 
pain.  When the cultured DRG neurons were treated with EMA401 and capsaicin was applied, 
there was a dose-dependent decrease of the capsaicin response and an inhibition of neurite 
outgrowth (Anand et al., 2013).  AT2R is found in sensory neurons of human dorsal root 
ganglion (DRG) and in peripheral nerves, intestines, and urinary bladder (Anand et al., 2013), 
indicating that the use of EMA401 may be beneficial in the management of peripheral 
neuropathic pain disorders.  Anand et al. (2015) suggest that EMA401 may act via 
“autocrine/intracrine in addition to paracrine mechanisms in DRG neurons, to reduce augmented 
neuropathic pain signaling” (p. 5), inhibiting DRG neuron hyperexcitability. 
EMA401 has demonstrated significant improvement in pain levels in persons with PHN.  
A multicenter, randomized, double-blind, placebo-controlled phase two clinical trial was 
completed with 92 patients receiving EMA401, 100 mg orally twice daily, and 91 patients 
receiving a placebo for a treatment duration of 28 days (Rice et al., 2014).  Participants were 
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eligible for inclusion in Rice et al.’s study if they had experienced PHN for at least six months 
after the onset of HZ rash; a total of 87 patients in the EMA401 group and 84 patients in the 
placebo group completed the treatment course.  The mean baseline pain rating on a numerical 
rating scale (NRS) of 0-10, with 10 being the worst pain, was 6.31 for the EMA401 treatment 
group and was 6.33 for the placebo groups in Rice et al.’s study.  Participants’ mean duration of 
pain was 2.02 years for the EMA401 treatment group and 2.06 years for the placebo group (Rice 
et al., 2014). 
The primary endpoint in this study was the change in mean NRS pain level from baseline 
to the last week of the trial (Rice et al., 2014).  Over this time period, Rice et al. observed a mean 
decrease of 2.289 (P=0.0066) on the NRS in participants receiving EMA401 compared to a 
decrease of 1.601 in those receiving a placebo over the same time period.  Secondary endpoints 
in Rice et al.’s study were the onset and maintenance of effect and the proportion of participants 
achieving a ≥ 30% reduction in mean pain score.  57.6% of participants in the EMA401 
treatment group achieved a ≥ 30% reduction in NRS score from baseline to week four 
(P=0.0023) and 33.7% of participants achieved a ≥ 50% decrease in NRS pain score by week 
four (P=0.0210) (Rice et al., 2014).  Rice et al.’s study also found the NNT with EMA401 to 
achieve a ≥ 30% or a ≥ 50% reduction in pain at week four was 4.46 and 6.66, respectively; this 
is comparable to currently approved and used first-line treatments.  Tertiary endpoints in Rice et 
al.’s study included various quality of life measurements.  There were no statistically significant 
differences between the treatment group and the placebo group in regard to the Depression, 
Anxiety, and Positive Outlook Scale or the Pain Catastrophizing Scale (Rice et al., 2014).  There 
was a significant improvement in the Patient Global Impression of Change survey with 42.4% of 
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patients reporting that their pain was “much improved” or “very much improved” at day 28 
(P=0.0096) (Rice et al., 2014). 
The analgesic efficacy provided by EMA401 is comparable to other first-line treatments 
for PHN (Rice et al., 2014).  No serious adverse effects were observed or reported in Rice et al.’s 
research and no notable changes occurred in the cardiovascular or renal systems from baseline.  
EMA401 was also well tolerated by patients in Rice et al.’s study, with only one person 
withdrawing from the treatment group compared to three patients withdrawing from the placebo 
group due to adverse effects.  While the current first-line treatments are dose-limited due to side 
effects, EMA401 has proven to be well tolerated in clinical trials (Rice et al., 2014).  In regard to 
the lack of adverse central nervous system side effects, this is consistent with EMA401’s 
inability to cross the blood brain barrier (Anand et al., 2013).  EMA401 presents as a novel 
therapeutic compound as there are no currently existing clinically available medications that 
target the AT2R system (Smith & Muralidharan, 2015).   
HZ/su Vaccine 
Primary prevention is another method of reducing the burden of chronic neuropathic pain 
due to PHN.  When examining the efficacy of the currently administered varicella vaccination, 
there have been inconsistent data.  Some studies have shown no change in the incidence of HZ 
over the decades while others have shown an increase in incidence; it is unclear why the 
incidence of HZ appears to be increasing (Kawai et al., 2014).   
The current live-attenuated vaccine against HZ, Zostavax, is approved for adults 50 years 
of age and older and has a 51.3% efficacy against HZ and 66.5% efficacy in preventing PHN in 
participants aged 60 and greater (Oxman et al., 2005).  Its efficacy decreases with age to 37.6% 
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in persons greater than or equal to 70 years old (Oxman et al., 2005) and is contraindicated in 
persons with impaired immunity, such as persons receiving immunosuppressives, those with 
HIV and CD4 cell counts of 200/mm3, and those undergoing hematopoietic cell transplantation 
(Cohen, 2015).  A recombinant subunit vaccine is a potential alternate to the live vaccine, but it 
must be combined with immunoenhancing adjuvants to augment the immunogenicity and 
vaccine efficacy (Chlibek et al., 2013).  A phase three clinical trial of a varicella zoster 
glycoprotein E and AS01B adjuvant system (HZ/su) has been shown to significantly reduce the 
risk of HZ in adults 50 years of age and older (Lal et al., 2015).  With a meaningfully greater 
efficacy at preventing HZ infection, it theoretically should follow that the incidence of PHN 
would decrease as well. 
A randomized, placebo-controlled, phase three trial was performed in 18 countries in 
Europe, North America, Latin America, and Asia-Australia in persons 50 years of age and 
greater who had no history of HZ infection, no history of vaccination against varicella or HZ, 
and did not have an immunosuppressive condition (Lal et al., 2015).  In Lal et al.’s study, 15,411 
participants were randomized to either the placebo group or to the group which would receive 
two doses of the HZ/su vaccine.  This study showed the overall incidence of HZ was 0.3/1000 
person-years in the HZ/su cohort and 9.1/1000 person-years in the placebo cohort, corresponding 
to an overall vaccine efficacy of 97.2% (P<0.001) (Lal et al., 2015), in comparison to the 
currently administered HZ vaccine’s efficacy of 51.3% (Oxman et al., 2005).  Unlike the 
currently administered vaccine, efficacy did not wane with age (P<0.001) (Lal et al., 2015).  This 
supports the findings of the previous multicenter, placebo-controlled, randomized phase two trial 
evaluating immunogenicity of the HZ/su vaccine (Chlibek et al., 2013).  This is of clinical 
significance as the incidence and severity of HZ infections intensity with age (Oxman, 2010) as 
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does the incidence of PHN (Oxman et al., 2005).  There were no safety concerns identified in 
this trial, although patients receiving the HZ/su vaccine did report injection site and systemic 
reactions at a greater frequency than those receiving a placebo; however, the reactions did not 
affect participants’ receptiveness to receiving the second dose (Lal et al., 2015). 
Chlibek et al. (2014) has shown the adjuvanted vaccine to induce higher immune 
responses than the unadjuvanted formulations and that the series of two VZ/su vaccines results in 
a greater sustained immune response than a single dose administration.  The immunosenescence 
accompanying aging creates a decreased immunogenicity of the current live-attenuated vaccine 
(Chlibek et al., 2014).  With the novel HZ/su vaccine, this diminished immune response was not 
noted and the efficacy did not diminish with age (Chlibek et al., 2014).  A single group, phase 2 
trial was also conducted by Chlibek et al. (2016) to evaluate long-term immunogenicity of the 
HZ/su vaccine.  Chlibek et al.’s (2016) study built upon previous evidence and showed that 72 
months after the first dose of the HZ/su vaccine, the cell-mediated and humoral immune 
responses persisted above pre-vaccination levels.  Although no threshold of protection against 
HZ has been identified, a correlation can be made between the sustained immune response levels 
and the clinically appreciable protection provided (Chlibek et al., 2016). 
One of the theoretical potential advantages of the HZ/su vaccine is that it may be safe to 
use in those who are immunocompromised and ineligible for the current HZ vaccination as it 
contains only a single virus protein, and the risk of disease from the virus replicating is 
eliminated (Cohen, 2015).  While it appears that the HZ/su vaccine is more effective than the 
currently administered vaccine in preventing HZ, there are no published reports of its effect on 
the development of PHN.  A trial has been completed examining the efficacy of the novel HZ/su 
vaccine in persons 70 years of age and greater with the secondary endpoints of the development 
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of PHN and the severity of neuropathic pain (GlaxoSmithKline, 2015); however, the results of 
this study have not yet been published.  If the results show a reduction in the development of 
PHN compared to the currently administered VZ vaccine, the HZ/su vaccine will truly be a novel 
and valuable agent as it would possess superior efficacy in preventing HZ as well as PHN. 
Neuromodulation 
 Several methods of peripheral nerve field neuromodulation have been assessed as 
treatments for PHN.  As early as 1974, chronic neuropathic pain has been treated with 
neurostimulation (Nathan & Wall, 1974).  Although neuromodulation has been in the literature 
for years in regard to the management of chronic neuropathic pain, the recent improvements in 
tools, methods, and understanding of neuromodulation have revived the interest. 
When looking at the overall success rate of peripheral nerve stimulation (PNS) on all 
types of neuropathic pain, there is a consistent 50% reduction in pain (Deogaonkar & Slavin, 
2014). Various invasive and noninvasive neurostimulation techniques have been evaluated in 
patients with a variety of refractory neuropathic pain with varied success.  PNS is one area that 
has had promising results, although the exact mechanism of action is unknown (Zibly, Sharma, 
Shaw, & Deogaonkar, 2014).  Several hypotheses put forth by Zibly et al. include: local 
alteration of blood flow, blocking depolarization and nerve conduction, altering the 
neurotransmitter potency, decreasing the pain threshold, increasing endogenous endorphin 
production, and blocking nociceptive input to the spinal cord.  
A retrospective review of four patients with thoracic PHN which had been unresponsive 
to medications and nerve blocks was completed by Zibly et al. (2014) to assess pain reduction in 
persons with an implanted permanent lead stimulator.  In Zibly et al.’s study, the duration of 
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PHN ranged from 3-8 years with an average baseline NRS pain score of 9 (range 7-10).  Prior to 
implantation, a seven day trial was done to confirm at least a 50% reduction in pain on the NRS; 
patients then proceeded with permanent subcutaneous implantation of a stimulation unit, which 
ensures that the leads are not too deep as to cause muscle twitching and not too shallow to cause 
a burning sensation or skin erosion (Zibly et al., 2014).  The average NRS pain score was 2.5 ± 
1.3 at the time of last follow-up (average 28.25 ± 11.6 months), equating to pain reduction of 67-
88% (Zibly et al., 2014).  While it was a small study, this retrospective review demonstrated an 
effective and safe alternative mechanism for chronic pain related to PHN which is unresponsive 
to traditional methods.  Further research with a larger patient group is needed to determine the 
significance and applicability to larger populations. 
A peripheral nerve field stimulation study was conducted in Italy involving 22 
participants with a variety of causations of neuropathic pain, eight of which were affected by 
PHN (D'Ammando, Messina, Franzini, & Dones, 2016).  D’Ammando et al.’s study involved the 
implantation of subcutaneous leads which were then anchored.  D'Ammando et al.’s research 
showed that persons affected by PHN achieved some of the best outcomes, particularly when the 
pain involved the craniofacial region.  The baseline pain score on the NRS was 8.83 in persons 
with PHN; patients were followed for 60 months after implantation and reported an average NRS 
pain score of 3.16, which is a reduction of 5.66 (D'Ammando et al., 2016).  No p-values were 
provided.  This study did find variability in efficacy dependent on location and cause of 
neuropathic pain; however, the results in the treatment of PHN appear promising.  Some of the 
best results were shown in persons with PHN affecting the craniofacial area, while some of the 
least improvements in pain were in persons with failed back surgery affecting the perineal region 
(D'Ammando et al., 2016). 
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A novel method of peripheral modulation has been evaluated which does not require 
implantation of a device.  The percutaneous electrical nerve stimulation (PENS) method studied 
by Rossi et al. (2016) used bipolar, fine-gauge needles inserted through the skin through which 
an alternating electrical stimulation was delivered; the needles were then removed at the end of 
the treatment session.  This new device may provide the ability to deliver a single episode of 
treatment with long-term efficacy and lessened risks of ongoing complications, such as infection, 
erosion or migration of electrode (Rossi et al., 2016).  
Eighty-two participants enrolled in Rossi et al.’s (2016) study, of which 21 patients had 
PHN.  The mean duration of neuropathic pain in all patients in Rossi et al.’s study was 39.7 ± 
17.6 months.  All patients underwent the first PENS treatment, with 7 of 82 (8.5%) requiring a 
second (Rossi et al., 2016).  Pain intensity was reduced at 60 minutes following PENS and 
remained constant over time until the end of follow-up at 6 months post-PENS (Rossi et al., 
2016).  Baseline median pain rating on the NRS was 8 (IQ 7-10) and at 60 minutes after PENS 
was reduced to 3 (0-5) (P<0.001) (Rossi et al., 2016).  The Euroqol-5 Dimension (EQ-5D) tool 
was also used to evaluate efficacy of PENS treatment in Rossi et al.’s study; this tool measures 
quality of life in 5 dimensions, such as pain/discomfort and anxiety/depression.  The EQ-5D 
increased significantly at six months follow-up as compared to baseline (P<0.001), 
demonstrating not only advances in pain management, but overall improvements in quality of 
life as well (Rossi et al., 2016).  Further research needs to be done to determine if there is greater 
efficacy in patients with specific origins or locations of neuropathic pain.  Initial research shows 
PENS to be a promising, single-treatment modality in the management of refractory PHN.     
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Summary 
As PHN can be a devastating consequence to HZ infection and current treatment options 
only provide modest results, it is important that we continue to research potential therapeutics 
(Kawai et al., 2014).  Some of the key points in the prevention and management of PHN are: 
• Offer to and encourage all eligible patients to receive Zostavax  
• Antivirals do not reduce the risk of developing PHN (Chen et al., 2014) 
• An updated treatment algorithm is available online at 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4493167/ (Finnerup et al., 2015) 
• Providers should be watching for several novel therapies that were found to have equal, if 
not greater, efficacy in early studies compared to the current treatments.  These include: 
EMA401, a highly selective angiotensin II type 2 receptor antagonist, HZ/su, a novel 
conjugate VZ subunit vaccine, and various modes of neuromodulation.   
As knowledge continues to grow in the management of complex, neuropathic disorders, 
pharmacologic and nonpharmacologic treatments will continue to be developed.  Further 
research specific to PHN management is needed, as well as focus into what treatments are most 
efficacious for the various dermatome regions commonly affected.  The above discussed 
therapies show promise to be more effective than our current preventative and management 
measures.  As our elderly and immunocompromised population continues to grow, the incidence 
of HZ and its most common complication, PHN, can be projected to rise as well.  Effective 
prevention of HZ and treatment of PHN are needed not only to manage pain but also to preserve 
quality of life in this vulnerable population.  
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